YOSHIO YAMAOKA to Clarithromycin
This is a "connection" page, showing publications YOSHIO YAMAOKA has written about Clarithromycin.
Connection Strength
2.080
-
Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014 Jul; 69(7):1796-803.
Score: 0.410
-
Identification of genetic determinants of antibiotic resistance in Helicobacter pylori isolates in Vietnam by high-throughput sequencing. BMC Microbiol. 2025 May 02; 25(1):264.
Score: 0.221
-
Benefits of a Molecular-Based Method for the Detection of Clarithromycin-Resistant Helicobacter pylori. Gut Liver. 2021 07 15; 15(4):487-489.
Score: 0.170
-
Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel). 2020 07 24; 12(8).
Score: 0.159
-
Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan. Int J Infect Dis. 2020 Aug; 97:102-107.
Score: 0.157
-
Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg. 2017 May; 96(5):1050-1059.
Score: 0.125
-
Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016; 11(12):e0166199.
Score: 0.124
-
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016 11 04; 16(1):256.
Score: 0.123
-
Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. World J Gastroenterol. 2014 Mar 28; 20(12):3343-9.
Score: 0.103
-
Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol. 2012 Apr; 46(4):297-301.
Score: 0.089
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
Score: 0.052
-
Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low? Gut. 2024 01 05; 73(2):374-375.
Score: 0.051
-
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
Score: 0.050
-
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024 01; 9(1):56-67.
Score: 0.050
-
Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000 Aug; 44(8):2214-6.
Score: 0.040
-
Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
Score: 0.033
-
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017 10; 2(10):707-715.
Score: 0.032
-
Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. Asian Pac J Cancer Prev. 2016; 17(1):285-7.
Score: 0.029
-
Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter. 2014 Oct; 19(5):387-99.
Score: 0.026
-
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
Score: 0.014
-
Antimicrobial activity of essential oils against Helicobacter pylori. Helicobacter. 2003 Jun; 8(3):207-15.
Score: 0.012
-
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. J Gastroenterol Hepatol. 1998 Jul; 13(7):732-7.
Score: 0.009